Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NXGLNASDAQ:PETVNASDAQ:PSTVNYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNXGLNEXGEL$2.19-0.9%$2.59$1.84▼$5.10$16.76M0.6568,351 shs38,882 shsPETVPetVivo$0.77-4.1%$0.63$0.29▼$0.98$18.57M0.7820,877 shs67,323 shsPSTVPlus Therapeutics$0.28-1.2%$0.68$0.24▼$2.67$4.81M0.884.59 million shs18.40 million shsRVPRetractable Technologies$0.65-4.4%$0.71$0.56▼$1.22$19.46M1.6574,357 shs26,412 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNXGLNEXGEL0.00%+0.46%-17.67%-23.16%+5.29%PETVPetVivo0.00%-4.24%+21.41%+39.37%+21.60%PSTVPlus Therapeutics0.00%-5.38%-56.34%-57.14%-87.20%RVPRetractable Technologies0.00%+0.15%-12.16%-18.65%-38.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNXGLNEXGEL1.4043 of 5 stars0.05.00.00.02.72.50.0PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics1.4025 of 5 stars3.32.00.00.01.60.00.6RVPRetractable TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNXGLNEXGEL 0.00N/AN/AN/APETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$11.503,965.04% UpsideRVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PSTV, RVP, PETV, and NXGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/17/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNXGLNEXGEL$10.23M1.64N/AN/A$0.90 per share2.43PETVPetVivo$1.05M17.75N/AN/A($0.03) per share-25.54PSTVPlus Therapeutics$4.91M0.98N/AN/A($0.30) per share-0.94RVPRetractable Technologies$33.75M0.58$0.01 per share48.25$3.31 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNXGLNEXGEL-$3.16M-$0.45N/A∞N/A-52.60%-71.19%-34.79%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)PSTVPlus Therapeutics-$13.32M-$2.50N/AN/AN/A-225.07%N/A-154.56%6/4/2025 (Estimated)RVPRetractable Technologies-$7.01M-$0.77N/A∞N/A-41.11%-17.15%-9.33%N/ALatest PSTV, RVP, PETV, and NXGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/13/2025Q1 2025NXGLNEXGEL-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNXGLNEXGELN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNXGLNEXGEL0.191.510.93PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A0.440.44RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNXGLNEXGEL2.21%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipNXGLNEXGEL20.55%PETVPetVivo10.84%PSTVPlus Therapeutics3.76%RVPRetractable Technologies57.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNXGLNEXGEL107.66 million5.10 millionNot OptionablePETVPetVivo2024.23 million19.06 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionablePSTV, RVP, PETV, and NXGL HeadlinesRecent News About These CompaniesWall Street Zen Initiates Coverage on Retractable Technologies (NYSE:RVP)May 23, 2025 | americanbankingnews.comThomas J. Shaw Buys 86,014 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 17, 2025 | insidertrades.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025 | RVP Stock NewsMay 15, 2025 | gurufocus.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025May 15, 2025 | businesswire.comRetractable Technologies, Inc. (NYSE:RVP) CEO Buys $10,037.25 in StockMay 15, 2025 | insidertrades.comThomas J. Shaw Purchases 22,620 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 7, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Buys 16,165 Shares of StockApril 24, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Purchases 33,524 Shares of StockApril 15, 2025 | insidertrades.comLittle Elm's Retractable Technologies announces 7% workforce reduction due to tariffsApril 11, 2025 | starlocalmedia.comRetractable Technologies cuts workforce to reduce reliance on China amid trade warApril 11, 2025 | drugdeliverybusiness.comRetractable Technologies announces 7% workforce reductionApril 11, 2025 | markets.businessinsider.comRetractable Technologies, Inc. Announces Reduction in WorkforceApril 10, 2025 | businesswire.comRetractable Technologies, Inc. Reports Results for 2024March 28, 2025 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | investing.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | businesswire.comThomas J. Shaw Buys 18,227 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockFebruary 5, 2025 | insidertrades.comRetractable Technologies CEO Thomas Shaw acquires $14,082 in stockFebruary 4, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Acquires $10,080.45 in StockJanuary 29, 2025 | insidertrades.comRetractable technologies CEO Thomas Shaw acquires shares worth $10,105January 28, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Purchases $22,707.36 in StockJanuary 24, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, RVP, PETV, and NXGL Company DescriptionsNEXGEL NASDAQ:NXGL$2.19 -0.02 (-0.90%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$2.17 -0.02 (-0.91%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.PetVivo NASDAQ:PETV$0.77 -0.03 (-4.11%) As of 05/30/2025 11:29 AM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.28 0.00 (-1.22%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.40 +0.12 (+41.39%) As of 08:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Retractable Technologies NYSE:RVP$0.65 -0.03 (-4.41%) Closing price 05/30/2025 03:58 PM EasternExtended Trading$0.65 0.00 (0.00%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
